ERBB2 and neoplasm: Collectively, these findings together indicated that TNBC with distinct HER2 phenotypes have different immune states of the tumor microenvironment; HER2neg TNBC reveals a more active state of immune microenvironment which is crucial for promoting the response of immunotherapies (Additional file 8).